A legal case seeking to reverse the Pentagon’s revocation of some GLP-1 drug coverage for TRICARE For Life beneficiaries has made headlines thanks to courtroom drama … but the unfair underlying policy remains the real story for MOAA and all military retirees, both present and future.

Rudy Renfer, a Justice Department lawyer assigned to the case, was fired March 13, a day after he attempted to resign upon the court’s discovery of his error-filled court filing produced with the help of artificial intelligence (AI). The retired officer who filed the suit – Col. Derence Fivehouse, USAF (Ret), a MOAA member and a former Air Force lawyer – reported the errors to Judge Robert T. Numbers, who expressed “serious concerns” about Renfer’s explanation of the filing, which included fabricated quotations and other inaccuracies.

[MOAA MEMBER PUBLICATION: Transitioning Into Medicare and TRICARE For Life]

The high-profile firing and the ongoing concern in the legal community surrounding “AI hallucinations” led to a flurry of news reports. Few of the reports looked into the heart of the case: The Pentagon’s 2025 decision to end coverage of GLP-1 drugs under TRICARE For Life while maintaining it in similar circumstances for other TRICARE users.

Since the move, which took effect Aug. 31, MOAA has worked to reverse the coverage change, engaging with lawmakers and Defense Health Agency officials.

Some non-AI-generated background:

• The change effectively establishes two classes of drug coverage: One for TRICARE, one for TRICARE For Life. MOAA believes this setup goes against the intent of Congress in its establishment of the TRICARE Pharmacy program.
  
  
• Should this dual-track coverage move forward, it would set a dangerous precedent – other drugs could be added to the TRICARE-approved list but remain excluded from the TRICARE For Life coverage, weakening an earned benefit relied upon primarily by uniformed services retirees and their families.
  
  
• GLP-1 users who’ve seen improvements while taking this medication face a stark choice: Pay sometimes-exorbitant costs to continue the medication outside of their prescription plan or risk the progress they’ve made … and their overall health.

[UPDATED MONTHLY: MOAA’s TRICARE Toolkit]

GLP-1 Basics

All TRICARE users, to include those using TRICARE For Life, retain GLP-1 coverage if the drug is prescribed to treat Type 2 diabetes. But only TRICARE Prime and Select users retain GLP-1 coverage for weight loss; they must meet strict prior-authorization standards and have a comorbid condition such as sleep apnea or metabolic dysfunction.

TRICARE For Life users also needed to meet those requirements prior to the Aug. 31 discontinuation of coverage, and would need to do so again if the coverage is restored.

Confusion over the use of GLP-1 medication for cosmetic purposes – a benefit not covered under any TRICARE plan and not sought by MOAA – may hinder efforts to reverse the Pentagon’s decision. And the recent AI-generated publicity may spotlight a court case involving this unfair policy change.

But the bottom line for MOAA remains the same: We will fight to reverse this move, and to restore drug coverage parity for TRICARE and TRICARE For Life users, not just for the hundreds of beneficiaries who’ve already shared their story with us, but for future retirees and family members who will transition into TRICARE For Life coverage in the coming years.

Keep up with new information on this issue and other MOAA priorities at MOAA’s news page.